Meta ‑analysis of the efficacy of venetoclax and azacitidine combination therapy and azacitidine monotherapy for treating acute myeloid leukemia

In conclusion, the combination of venetoclax and azacitidine was more effective than azacitidine alone, and had a good clinical application value in the treatment of AML. Although some adverse reactions occurred in response to the combination therapy, they did not significantly affect the prognosis of AML. To better evaluate the efficacy and safety of this treatment regimen, multicenter clinical studies with larger sample sizes are required.PMID:38476897 | PMC:PMC10928973 | DOI:10.3892/etm.2024.12452
Source: Experimental and Therapeutic Medicine - Category: General Medicine Authors: Source Type: research